Zivo Bioscience, Inc. financial data

Symbol
ZIVO, ZIVOW on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
21 E. Long Lake Road, Suite 100, Bloomfield Hills, MI
State of incorporation
NV
Fiscal year end
December 31
Former names
HEALTH ENHANCEMENT PRODUCTS INC (to 10/16/2014), WESTERN GLORY HOLE INC (to 1/26/2004)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 30.1 % -53.6%
Debt-to-equity -151 % +54.8%
Return On Assets -1.31K % -199%
Operating Margin -21.9K % +89.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.37M shares -67.8%
Common Stock, Shares, Outstanding 3.32M shares -64.8%
Entity Public Float 17.3M USD -38.9%
Common Stock, Value, Issued 3.32K USD -64.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 59.3K USD +1365%
Revenue from Contract with Customer, Excluding Assessed Tax 59.3K USD -100%
Research and Development Expense 3.1M USD +57.6%
General and Administrative Expense 9.9M USD +53%
Operating Income (Loss) -13M USD -53.9%
Nonoperating Income (Expense) -13.3K USD +88%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -13.2M USD -52.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.8M USD -79.8%
Assets, Current 495K USD -6.59%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 48.4K USD -66.7%
Assets 576K USD -19%
Accounts Payable, Current 1.09M USD -14.1%
Accrued Liabilities, Current 1M USD +47.1%
Liabilities, Current 2.87M USD -24.5%
Long-term Debt and Lease Obligation 132K USD
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 2.87M USD -25.5%
Retained Earnings (Accumulated Deficit) -133M USD -11.1%
Stockholders' Equity Attributable to Parent -2.3M USD +27%
Liabilities and Equity 576K USD -19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.7M USD +20.2%
Net Cash Provided by (Used in) Financing Activities 1.56M USD +190%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 25M shares -83.3%
Common Stock, Shares, Issued 2.38M shares +51.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 274K USD -84.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.06K USD -13.5%
Deferred Tax Assets, Valuation Allowance 12.4M USD +14.7%
Deferred Tax Assets, Gross 10.8M USD +18.7%
Operating Lease, Liability 132K USD -41%
Lessee, Operating Lease, Liability, to be Paid 142K USD
Property, Plant and Equipment, Gross 100K USD 0%
Operating Lease, Liability, Current 50.9K USD -52.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 112K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 29.5K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.47K USD -68.1%
Preferred Stock, Shares Issued 3.32M shares -64.8%
Additional Paid in Capital 131M USD +12.1%
Deferred Tax Assets, Net of Valuation Allowance 12.4M USD +14.7%
Share-based Payment Arrangement, Expense 571K USD -41.5%
Interest Expense -1.55K USD -104%